Онкогематология (Nov 2022)

Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis)

  • N. N. Savva,
  • O. V. Kras'ko,
  • M. V. Belevtcev,
  • V. P. Savitckiy,
  • N. V. Migal,
  • O. V. Aleinikova

DOI
https://doi.org/10.17650/1818-8346-2009-0-2-17-21
Journal volume & issue
Vol. 0, no. 2
pp. 17 – 21

Abstract

Read online

220 children with acute lymphoblastic leukemia (ALL) treated according to ALL-MB-2002 protocol are included in the study. Minimal residual disease (MRD) estimated in bone marrow by three-color flow cytometry on day 15 (n=99), day 36 (n=107) and before the maintenance therapy (n=60). Day 36 positive MRD level (≥0.01%) as one of unfavorable factors statistically significant worsening of relapse-free survival was revealed (log-rank test; р<0.05). In multifactorial analysis (Cox regression) it is revealed that positive MRD level on day 36 of treatment is the strongest and independent prognostic factor influencing relapse probability (hazard ratio 6.6; p=0.031). Necessity of additional patients' stratification introduction according to MRD level after induction is proved.

Keywords